Skip to main content
main-content

Small-cell lung cancer

Latest articles

03-08-2020 | Oncology | News | Article

EMA recommends new indication for durvalumab

Click through to find out more

17-06-2020 | Oncology | News | Article

Lurbinectedin approved for US metastatic SCLC patients

Click through to read more

28-04-2020 | Oncology | News | Article

Camrelizumab–apatinib has antitumor activity in previously treated SCLC patients

Phase 2 PASSION trial data point to the potential of camrelizumab plus apatinib for the second-line treatment of extensive-stage small-cell lung cancer.

06-03-2020 | Oncology | News | Article

miRNA profiles represent potential noninvasive biomarker for lung cancer diagnosis

Researchers have identified microRNA signatures that can potentially distinguish symptomatic patients with lung cancer from healthy people as well as those with other lung and non-lung diseases.

29-01-2020 | Oncology | News | Article

QoL, safety data boost evidence for atezolizumab–chemotherapy regimen in ES-SCLC

Adding atezolizumab to carboplatin plus etoposide does not lead to substantially more adverse events than placebo and does not adversely affect health-related quality of life in patients with extensive-stage small-cell lung cancer, IMpower 133 trial data show.

14-10-2019 | Oncology | News | Article

Olaparib–temozolomide combination has ‘substantial’ activity in relapsed SCLC

A phase I/II trial has shown promising efficacy and tolerability for the combination of the PARP inhibitor olaparib with temozolomide in patients with previously treated small-cell lung cancer.

03-10-2019 | Oncology | News | Article

CASPIAN: Adding durvalumab to chemotherapy improves SCLC PROs

The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.

18-09-2019 | Oncology | News | Article

Trilaciclib shows myelopreservation benefits in patients with SCLC

Trilaciclib affords myelopreservation in individuals with small-cell lung cancer treated with first-line chemotherapy, without impacting treatment efficacy, research indicates.

09-09-2019 | Small-cell lung cancer | News | Article

CASPIAN: Durvalumab addition boosts SCLC survival

Adding durvalumab to first-line chemotherapy significantly improves the overall survival of patients with extensive-stage small-cell lung cancer, a phase III trial shows.

09-09-2019 | Oncology | News | Article

irAEs linked to SCLC immunotherapy clinical benefit

The development of immune-related adverse events is associated with improved clinical outcomes in response to immune checkpoint blockade in patients with small-cell lung cancer, suggests a chart review.

25-06-2019 | Oncology | News | Article

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

07-06-2019 | Oncology | News | Article

Lurbinectedin shows potential for second-line SCLC treatment

Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

24-05-2019 | Oncology | News | Article

Twice-daily radiotherapy may increase brain metastasis risk in SCLC

Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.

17-05-2019 | Oncology | News | Article

CTCs prognostic in limited-stage SCLC

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

02-04-2019 | Oncology | News | Article

Pembrolizumab supported for third- or later-line extensive-stage SCLC

Single-agent pembrolizumab could be a promising option for extensive-stage small-cell lung cancer patients who have received at least two prior lines of therapy, suggests a pooled analysis of data from the multicohort KEYNOTE-028 and -158 trials.

25-03-2019 | Oncology | Main feed | News

FDA approves atezolizumab for extensive-stage SCLC

Click here to read more on this announcement

21-12-2018 | Non-small-cell lung cancer | News | Article

Clinical course of EGFR-mutant NSCLC transforming to SCLC documented

Epidermal growth factor receptor-mutant non-small-cell lung cancer that transforms to small-cell lung cancer is characterized by a high rate of TP53 mutation and a lack of response to immunotherapy, among other features, show researchers.

14-12-2018 | Small-cell lung cancer | News | Article

Veliparib shows efficacy in some patients with extensive-stage SCLC

Some patients with extensive-stage small-cell lung cancer may benefit from the addition of the poly(ADP ribose) polymerase inhibitor veliparib to standard chemotherapy, but further confirmation of its efficacy is needed, say researchers.

27-09-2018 | Oncology | News | Article

Atezolizumab–chemotherapy combination boosts extensive-stage SCLC survival

The addition of atezolizumab to chemotherapy has significantly improved both the overall survival and progression-free survival of treatment naïve-patients with extensive-stage small-cell lung cancer, results from the IMpower133 trial indicate.

Image Credits